← Eichor
Condition: Bispecific Antibody Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Bispecific Antibody

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Phase 1 · 18 location(s) · Regeneron Pharmaceuticals · NCT06975787A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors
Phase 1 · 7 location(s) · Shanghai Henlius Biotech · NCT07473726AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05377658A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Part
Phase 1 · 42 location(s) · Regeneron Pharmaceuticals · NCT05137054A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · Akeso · NCT06929663Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Phase 1 · 1 location(s) · University of Virginia · NCT07270978Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Phase 1 · 9 location(s) · BioAtla, Inc. · NCT05808634A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Phase 1 · 7 location(s) · Light Chain Bioscience - Novimmune SA · NCT05403554ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106710PM8002 in the Treatment of Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 48 location(s) · Biotheus Inc. · NCT05918445A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
Phase 4 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT06930573A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Benefi
Phase 1/Phase 2 · 68 location(s) · BioNTech SE · NCT07111520A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 · 3 location(s) · ABL Bio, Inc. · NCT06126666Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic H
Phase 1 · 91 location(s) · AstraZeneca · NCT04686305An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06799611First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Phase 1 · 4 location(s) · Onward Therapeutics · NCT05828459A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
Phase 1 · 8 location(s) · NEOK Bio, Inc. · NCT07612176Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Phase 1/Phase 2 · 87 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT04930432A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet
Phase 2 · 71 location(s) · Bristol-Myers Squibb · NCT07680764A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined
Phase 3 · 168 location(s) · Regeneron Pharmaceuticals · NCT06091865M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid
Phase 1 · 5 location(s) · EMD Serono Research & Development Institute, Inc. · NCT07166601A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chem
Phase 2 · 24 location(s) · BioNTech SE · NCT07255404The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma
Phase 1 · 2 location(s) · University Hospital Tuebingen · NCT04104607A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With
Phase 3 · 109 location(s) · Janssen Research & Development, LLC · NCT07258511A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease
Phase 2 · 1 location(s) · Shandong First Medical University · NCT06900010A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Phase 3 · 2 location(s) · Regeneron Pharmaceuticals · NCT07393282A Study of GR1803 in Systemic Lupus Erythematosus
Phase 1/Phase 2 · 1 location(s) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · NCT07348055Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Phase 2 · 54 location(s) · Regeneron Pharmaceuticals · NCT06787612HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
Phase 1/Phase 2 · 1 location(s) · University of Virginia · NCT07441889FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer
Phase 1 · 1 location(s) · German Cancer Research Center · NCT05999396
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.